Up to $125 million Oaktree loan facility to support OXB’s global CDMO operations and growth strategy $60 million upfront to repay existing $50 million loan facility and for general corporate purposes Facility provides flexibility to draw down additional funds to support future business needs, if required Oxford, UK – 1… Read More
Continued commercial, financial and operational momentum as OXB executes on its multi-vector, multi-site strategy H1 2025 revenues of £70-73 million, an increase of 38%-44% vs. £51 million at H1 2024 Commercial momentum accelerating, with £149 million new orders1 signed during H1 2025, more than double the £56 million orders signed… Read More
Oxford, UK – 23 June 2025: OXB (LSE: OXB) (“the Company”), a global quality and innovation-led cell and gene therapy CDMO, today announces that it has acquired the remaining 10% stake in its US subsidiary from Q32 Bio, Inc. (Q32), bringing its ownership, as planned, to 100%. As previously disclosed in… Read More
Oxford, UK – 16 June 2025: OXB has been ranked 34th out of 300 organisations in Fortune’s list of Europe’s most innovative companies, a recognition that underscores the company’s leadership in cell and gene therapy innovation. The list, compiled based on evaluations by industry experts and employees, highlights businesses delivering… Read More
Annual General Meeting being held at 3pm BST today at Windrush Court, Oxford, UK The Company remains on track to deliver the outlook set out in the Preliminary Results published on 9 April 2025 Oxford, UK – 11 June 2025: OXB (LSE: OXB) (“the Company”), a global quality and innovation-led cell… Read More
Oxford, UK – 03 June 2025: OXB (LSE: OXB) (“the Company”), a global quality and innovation-led cell and gene therapy CDMO, today highlights the launch of its Innovation and Technology Excellence Board (ITEB). The ITEB brings together leading experts in cell and gene therapy, scientific innovation, and advanced manufacturing. It will… Read More
Oxford, UK – 8 May 2025: OXB (LSE: OXB), a global quality and innovation-led cell and gene therapy CDMO, today announces its participation in the 28th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT), taking place from 13–17 May 2025 at the Ernest N. Morial Convention Center… Read More
Oxford, UK – 28 April 2025: OXB (LSE: OXB), a global quality and innovation-led cell and gene therapy CDMO, gives notice that the Notice of Annual General Meeting (“AGM”) together with a copy of the 2024 Annual report and accounts are being sent to shareholders today. These documents are available on… Read More
Strong 2024 financial performance in line with guidance Revenue growth of 44% to £128.8 million compared to 2023, organic revenue growth of 81%1 Operating EBITDA2 loss of £(15.3) million for the full year in line with expectations, Operating EBITDA profit of £5.0 million achieved in second half of 2024 Contracted… Read More
Oxford, UK – 21 March 2025: OXB (LSE: OXB) (the “Company”), a quality and innovation-led cell and gene therapy CDMO, today announces that the Company has been recognised as a winner in the ‘Cell & Gene Therapy – Global’ category at the 2025 CDMO Leadership Awards. The annual CDMO Leadership Awards… Read More
Oxford, UK – 26 February 2025: OXB (LSE: OXB), a global quality and innovation-led cell and gene therapy CDMO, today announces that Dr. Lucinda Crabtree, Chief Financial Officer, will take part in a fireside chat at the Leerink Partners Global Healthcare Conference in Miami, Florida on Tuesday, 11 March 2025 at… Read More
Oxford, UK – 20 February 2025: OXB (LSE:OXB), a global quality and innovation-led cell and gene therapy CDMO, today announces that its proprietary lentiviral vector manufacturing technology will be used in Boehringer Ingelheim’s newly initiated LENTICLAIR™ 1 trial. The Phase I/II study is evaluating BI 3720931, a novel, first-in-class, inhaled… Read More